PharmaNutra’s Apportal supplement in testing to combat post-COVID-19 fatigue
13 Apr 2021 --- PharmaNutra reports positive preliminary results for its nutritional supplement Apportal in patients suffering from post-COVID-19 fatigue, also known as long COVID-19.
Apportal contains phytoextracts and amino acids, blended with nutrients that target immunity (vitamin C and D) and the muscular system (magnesium).
The mixture also contains antioxidants, such as coenzyme Q10, lycopene and energizing ingredients like taurine and ginseng.
First findings
In the first analyses of 100 patients taking the supplement 95 percent registered “significant benefit,” and the score indicating their fatigue improved by 64 percent.
Other findings suggest that women initially suffered more severe fatigue but showed a greater improvement in terms of mental fatigue.
Preliminary results suggest that the supplement improved patients’ quality of life and reduced fatigue. Therefore, ingredient synergies, such as those in Apportal, could be valuable for assisting consumers with persistent fatigue following COVID-19, claims the company.
PharmaNutra’s preliminary results showed that women suffered more severe initial fatigue while showing a greater improvement in terms of mental fatigue.Study details
The study, which is now in its final phase, involves 200 patients in Italy suffering from post-COVID-19 fatigue over a treatment course of 28 days.
The study was done with the assistance of general practitioners across Italy and included a wide age range of patients. Patients were included no matter the severity of their previous infection or which variant of the virus they had had.
Quality of life and degree of fatigue was measured for each patient at 0, 14 and 28 days while taking the supplement.
The FACIT-Fatigue questionnaire was used to assign a discrete fatigue value to the long COVID-19 patients. It is made up of 13 statements relating to the ability to perform everyday tasks, sleep needs during the day, energy and tiredness.
A second questionnaire created by re-adapting the Chalder Fatigue Scale was used to assess mental fatigue. These questions asked about memory, ability to concentrate and interest in activities performed before the infection.
The data obtained through the use of the FACIT-Fatigue Test for the first 100 patients showed that 95 percent of patients measured a significant benefit. The score indicating their fatigue improved by 64 percent.
Any differences among sexes were investigated and women suffered more severe initial fatigue while showing a greater improvement in terms of mental fatigue. This is congruent with current literature, which shows a higher degree of fatigue for women who have long COVID-19, the company notes.
Weary from the pandemic
Further studies will be needed to confirm these preliminary results that shed light on relieving the burden of long COVID-19.
Fatigue is one of the most common symptoms lasting for months after recovering from COVID-19. This condition is independent of the age of the subject and the severity of infection, notes the company.
In January, microbiome transplants were highlighted as potential solutions to tackle long COVID-19.
Edited by Missy Green
